Pfizer Inc., a leading global biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1849. With a strong presence in North America, Europe, and Asia, Pfizer operates across various sectors, including vaccines, oncology, and rare diseases. The company is renowned for its core products, such as the COVID-19 vaccine and groundbreaking cancer therapies, which leverage advanced biotechnology to address unmet medical needs. Pfizer's commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. With a robust portfolio and a reputation for quality, Pfizer continues to shape the future of healthcare, making a profound impact on global health outcomes.
How does Pfizer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pfizer's score of 83 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Pfizer reported total emissions of approximately 1,080,000,000 kg CO2e for Scope 1 and 2, while Scope 3 emissions included about 188,000,000 kg CO2e from business travel and approximately 154,000,000 kg CO2e from downstream transportation and distribution. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 46% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. This commitment aligns with their goal to procure 100% renewable electricity by 2030. Pfizer also aims to reduce Scope 3 emissions, targeting a 25% reduction in emissions from business travel and a 10% reduction from upstream transportation and distribution by 2025, both from a 2019 baseline. Furthermore, they have pledged that 64% of their suppliers by spend will have science-based targets by 2025. Looking towards the long term, Pfizer has committed to achieving net-zero emissions across its value chain by 2040, with a target to decrease company GHG emissions by 95% and value chain emissions by 90% from 2019 levels. These targets have been approved by the Science Based Targets initiative (SBTi), reinforcing Pfizer's commitment to climate action and sustainability.
Access structured emissions data, company-specific emission factors, and source documents
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.